H uman mAbs account for an increasing proportion of new drugs (1, 2). There have been major recent improvements in the way in which genetic information to encode Ag-specific mAbs can be obtained directly from human B cells (3) (4) (5) . However, such approaches are largely restricted to Ags such as infectious agents where individuals mounting a specific immune response can be identified and provide a source of Ag-specific B cells. For other Ags, approaches have been developed that either involve individual humanization of Ag-specific rodent Abs (which needs to be carried out on a case-by-case basis) or involve the selection of Ag-specific binders from human Ab repertoires performed outside the human body. The individual humanization of rodent mAbs is laborious because it needs to be carried out on a case-by-case basis with the V region sequence being manipulated (as well as the C region exchanged) to minimize immunogenicity (6) (7) (8) . The alternative strategy of obtaining Ag-specific human Abs by use of selections performed outside the human body typically employs either in vitro selection technologies (e.g., phage display) or in vivo Ag-mediated selection (i.e., immunization) in genetically engineered animals that express human Ab repertoires (9) (10) (11) (12) (13) (14) .
Thus, following immunization, Ag-specific human mAbs can be obtained by conventional hybridoma technology from transgenic mice whose B cell populations express human Ab repertoires. Indeed, in light of the potential importance of human mAbs as therapeutics, much effort has been devoted to creating improved mouse strains from which human mAbs can be more readily elicited ever since the first description of a mouse strain carrying an artificially constructed rearranging human IgH minilocus (15) . In most of the published mouse strains currently under use, segments of the human IgH and IgL loci comprising differing numbers of human V, D, and J segments linked to human C regions have been integrated into the mouse germline (16, 17) with the endogenous mouse Ig loci having been rendered nonfunctional through targeted gene disruption (18) .
Many human mAbs have been generated from transgenic lines by this strategy with six of eight fully human mAbs approved by the U.S. Food and Drug Administration (panitumumab, ofatumumab, golimumab, denosumab, ustekinumab, ipilimumab) and with further such mAbs currently being tested in phase II or III trials (http://en.wikipedia.org/wiki/List_of_monoclonal_antibodies) (1).
However, there is clearly room for improvement. Indeed, it has been suggested that suboptimal performance of these humanized mouse strains with regard to the efficacy with which they yield human mAbs might result from imperfect interaction between the C region of the human Ig expressed on the B cell membrane and the mouse cellular signaling machinery (19) . Because the transgenic mice can essentially be viewed as a source of Ag-specific IgV genes (with the desired IgC region provided at a later stage during the creation of cell lines for bulk Ab production), we wondered whether the transgenic approach could be improved if the germline configuration human IgV H -D-J H segments were linked to endogenous (rather than human) IgC H regions.
In this study, we describe a rat strain carrying entirely human IgL transloci but with an IgH translocus in which human IgV H , D, and J H segments have been linked to germline-configured rat IgC H regions. We find that this rat strain gives highly efficient chimeric Ab expression with serum IgM and IgG levels similar to those obtained with normal rats. Large numbers of high-affinity chimeric mAbs can also be readily established from these animals.
Materials and Methods

Construction of modified human Ig loci on yeast artificial chromosomes and bacterial artificial chromosomes
IgH loci. The human IgH V genes were covered by two bacterial artificial chromosomes (BACs): BAC6-V H 3-11 containing the authentic region spanning from V H 4-39 to V H 3-23 followed by V H 3-11 (modified from a commercially available BAC clone 3054M17 CITB) and BAC3 containing the authentic region spanning from V H 3-11 to V H 6-1 (811L16 RPCI-11). A BAC termed Annabel was constructed by joining rat C H region genes immediately downstream of the human V H 6-1-Ds-J H s region (Fig. 1A) . All BAC clones containing part of the human or rat IgH locus were purchased from Invitrogen. Oligonucleotides and PCR conditions are listed in the Supplemental Material.
Both BAC6-V H 3-11 and Annabel were initially constructed in Saccharomyces cerevisiae as circular yeast artificial chromosome (cYACs) and further checked and maintained in Escherichia coli as BACs. Unlike YACs, BAC plasmid preps yield large quantities of the desired DNA. To convert a linear YAC into a cYAC or to assemble DNA fragments with overlapping ends into a single cYAC in S. cerevisiae, which can also be maintained as a BAC in E. coli, two self-replicating S. cerevisiae/E. coli shuttle vectors, pBelo-CEN-URA and pBelo-CEN-HYG, were constructed. Briefly, S. cerevisiae CEN4 was cut out as an AvrII fragment from pYAC-RC (20) and ligated to SpeI-linearized pAP599 (21) . The resulting plasmid contains CEN4 cloned in between S. cerevisiae URA3 and a hygromycin-resistance expression cassette (Hyg R ). From this plasmid, an ApaLI-BamHI fragment containing URA3 followed by CEN4 or a PmlI-SphI fragment containing CEN4 followed by Hyg R was cut out and ligated to ApaLI and BamHI or HpaI and SphI doubly digested pBACBelo11 (New England BioLabs) to yield pBelo-CEN-URA and pBelo-CEN-HYG.
To construct BAC6-V H 3-11, initially two fragments, a 115-kb NotIPmeI and a 110-kb RsrII-SgrAI, were cut out from the BAC clone 3054M17 CITB. The 39 end of the former fragment overlaps 22 kb with the 59 end of the latter. The NotI-PmeI fragment was ligated to a NotIBamHI YAC arm containing S. cerevisiae CEN4 as well as TRP1/ARS1 from pYAC-RC, and the RsrII-SgrAI fragment was ligated to an SgrAIBamHI YAC arm containing S. cerevisiae URA3, also from pYAC-RC. Subsequently, the ligation mixture was transformed into S. cerevisiae AB1380 cells via spheroplast transformation (22) , and URA + TRP + yeast clones were selected. Clones, termed YAC6, containing the linear region from human V H 4-39 to V H 3-23 were confirmed by Southern blot analysis. YAC6 was further extended by addition of a 10.6-kb fragment 39 of V H 3-23 and conversion to a cYAC. The 10.6-kb extension contains the human V H 3-11 and also occurs at the 59 end of BAC3. We constructed pBeloHYG-YAC61BAC3(59) for the modification of YAC6. Briefly, three fragments with overlapping ends were prepared by PCR: 1) a "stuff" fragment containing S. cerevisiae TRP1-ARS1 flanked by HpaI sites with a 59 tail matching the sequence upstream of V H 4-39 and a 39 tail matching downstream of V H 3-23 in YAC6 (using long oligonucleotides 561 and 562, and pYAC-RC as template); 2) the 10.6-kb extension fragment with a 59 tail matching the sequence downstream of V H 3-23 as described above and a unique AscI site at its 39 end (using long oligonucleotides 570 and 412, and human genomic DNA as template); and 3) pBelo-CEN-HYG vector with the CEN4 joined downstream with a homology tail matching the 39 end of the 10.6 extension fragment and the Hyg R joined upstream with a tail matching the sequence upstream of V H 4-39 as described above (using long oligonucleotides 414 and 566, and pBelo-CEN-HYG as template). Subsequently, the three PCR fragments were assembled into a small cYAC conferring HYG R and TRP + in S. cerevisiae via homologous recombination associated with spheroplast transformation, and this cYAC was further converted into the BAC pBeloHYG-YAC61BAC3(59). Finally, the HpaI-digested pBeloHYG-YAC61BAC3(59) was used to transform yeast cells carrying YAC6, and through homologous recombination cYAC BAC6-V H 3-11 conferring only HYG R was generated. Via transformation (see below) this cYAC was introduced as a BAC in E. coli. The human V H genes in BAC6-V H 3-11 were cut out as an ∼182-kb AsiSI (occurring naturally in the Hyg R )-AscI fragment, and the V H genes in BAC3 were cut out as an ∼173-kb NotI fragment (Fig. 1A) .
For the assembly of the C region with the V H overlap, the human V H 6-1-Ds-J H s region had to be joined with the rat genomic sequence immediately downstream of the last J H followed by rat Cs to yield a cYAC/BAC. To achieve this, five overlapping restriction as well as PCR fragments were prepared: a 6.1-kb fragment 59 of human V H 6-1 (using oligonucleotides 383 and 384, and human genomic DNA as template), an ∼78-kb PvuI-PacI fragment containing the human V H 6-1-Ds-J H s region cut out from BAC1 (RP11645E6), a 8.7-kb fragment joining the human J H 6 with the rat genomic sequence immediately downstream of the last J H and containing part of rat m coding sequence (using oligonucleotides 488 and 346, and rat genomic DNA as template), an ∼52-kb NotI-PmeI fragment containing the authentic rat m, d, and g2c region cut out from BAC M5 (CH230-408M5) and the pBelo-CEN-URA vector with the URA3 joined downstream with a homology tail matching the 39 end of the rat g2c region and the CEN4 joined upstream with a tail matching the 59 region of human V H 6-1 as described (using long oligonucleotides 385 and 550, and pBelo-CEN-URA as template). Correct assembly via homologous recombination in S. cerevisiae was analyzed by PCR and purified cYAC from the correct clones was converted into a BAC in E. coli.
For the assembly of Annabel, parts of the above cYAC/BAC containing humanV H 6-1-Ds-J H s followed by the authentic rat m, d, and g2c region, as well as PCR fragments, were used. Five overlapping fragments contained the 6.1-kb fragment at the 59 end of human V H 6-1 as described above, an ∼83 kb SpeI fragment comprising human V H 6-1-Ds-J H s immediately followed by the rat genomic sequence downstream of the last J H and containing part of rat Cm, a 5.2-kb fragment joining the 39 end of rat m with the 59 end of rat g1 (using oligonucleotides 490 and 534, and rat genomic DNA as template), an ∼118-kb NotI-SgrAI fragment containing the authentic rat g1, g2b, ε, a, and 39E IgH enhancer region cut out from BAC I8 (CH230-162I08), and the pBelo-CEN-URA vector with the URA3 joined downstream with a homology tail matching the 39 end of rat 39E and the CEN4 joined upstream with a tail matching the 59 end of human V H 6-1 as described above. There is a 10.3-kb overlap between the human V H 6-1 regions in both the BAC3 and Annabel. The human V H 6-1-Ds-J H s followed by the rat C H region together with the S. cerevisiae URA3 in Annabel can be cut out as a single ∼193-kb NotI fragment (see Fig. 1A ).
BAC6-V H 3-11, BAC3, and Annabel were checked extensively by restriction analysis and partial sequencing for their authenticity. IgL loci. The human Igl locus on an ∼410-kb YAC was obtained by recombination assembly of a Vl YAC with 3 Cl containing cosmids (23) . Rearrangement and expression was verified in transgenic mice derived from ES cells containing one copy of a complete human Igl YAC (24) . This Igl YAC was shortened by the generation of a cYAC removing ∼100 kb of the region 59 of Vl3-27. The vector pYAC-RC was digested with ClaI and BspEI to remove URA3 and ligated with a ClaI/NgoMIV fragment from pAP 599 containing HYG (Fig. 1C) . PCR of the region containing the yeast centromere and hygromycin marker gene from the new vector (pYAC-RC-HYG) was carried out with primers with 59 ends homologous to a region 59 of Vl3-27 (primer 276) and within the ADE2 marker gene in the YAC arm (primer 275). The PCR fragment (3.8 kb) was integrated into the Igl YAC using a high-efficiency lithium acetate transformation method (25) and selection on hygromycin-containing yeast extract/peptone/dextrose plates. DNA was prepared from the clones (Epicentre MasterPure yeast DNA purification kit) and analyzed for the correct junctions by PCR using the following oligonucleotides: 243 plus 278 and Hyg end R plus 238. Plugs were made (26) and yeast chromosomes removed by pulsed field gel electrophoresis (PFGE; 0.8% agarose gel [pulse field certified; Bio-Rad) [6 V/cm, pulse times of 60 s for 10 h and 10 s for 10 h, 8˚C), leaving the cYAC caught in the agarose block (27) . The blocks were removed and digested with NruI. Briefly, blocks were preincubated with restriction enzyme buffer in excess at a 13 final concentration for 1 h on ice. Excess buffer was removed leaving just enough to cover the plugs, restriction enzyme was added to a final concentration of 100 U/ml, and the tube was incubated at 37˚C for 4-5 h. The linearized YAC was run out of the blocks by PFGE, cut out from the gel as a strip, and purified as described below.
For the human Igk locus three BACs were chosen (RP11-344F17, RP11-1134E24, and RP11-156D9; Invitrogen), which covered a region over 300 kb from 59 Vk1-17 to 39 KDE (28) . In digests and sequence analyses three overlapping fragments were identified: from Vk1-17 to Vk3-7 (150-kb NotI with ∼14-kb overlap), from Vk3-7 to 39 of Ck (158-kb NotI with ∼40-kb overlap), and from Ck to 39 of the KDE (55-kb PacI with 40-kb overlap) (Fig. 1B) . Overlapping regions may generally favor joint integration when coinjected into oocytes (29) .
Gel analyses and DNA purification
Purified YAC and BAC DNA were analyzed by restriction digest and separation on conventional 0.7% agarose gels (30) . Larger fragments (50-200 kb) were separated by PFGE (Bio-Rad CHEF Mapper) at 8˚C using 0.8% pulsed field-certified agarose in 0.5% TBE, at 2-20 s switch time for 16 h, 6 V/cm, 10 mA. Purification allowed a direct comparison of the resulting fragments with the predicted size obtained from the sequence analysis. Alterations were analyzed by PCR and sequencing.
Linear YACs, cYACs, and BAC fragments after digests were purified by electroelution using Elutrap (Schleicher and Schuell) (31) from strips cut from 0.8% agarose gels run conventionally or from PFGE. The DNA concentration was usually several nanograms per microliter in a volume of ∼100 ml. For fragments up to ∼200 kb the DNA was precipitated and redissolved in microinjection buffer (10 mM Tris-HCl [pH 7.5], 100 mM EDTA [pH 8], and 100 mM NaCl but without spermine/spermidine) to the desired concentration.
The purification of cYACs from yeast was carried out using NucleoBond AX silica-based anion-exchange resin (Macherey-Nagel, Düren, Germany). Briefly, spheroplasts were made using zymolyase or lyticase and pelleted (32) . The cells then underwent alkaline lysis, binding to AX100 column and elution as described in the NucleoBond method for a low-copy plasmid. Contaminating yeast chromosomal DNA was hydolyzed using Plasmid-Safe ATP-dependent DNase (Epicentre Biotechnologies) followed by a final cleanup step using SureClean (Bioline). An aliquot of DH10 electrocompetent cells (Invitrogen) was then transformed with the cYAC to obtain BAC colonies. For microinjection, the insert DNA (150-200 kb) was separated from BAC vector DNA (∼10 kb) using a filtration step with Sepharose 4B-CL (33).
Derivation of rats and breeding
Purified DNA encoding recombinant Ig loci was resuspended in microinjection buffer with 10 mM spermine and 10 mM spermidine. The DNA was injected into fertilized oocytes at various concentrations from 0.5 to 3 ng/ml. Plasmid DNA or mRNA encoding zinc finger nucleases (ZFNs) specific for rat Ig genes were injected into fertilized oocytes at various concentrations from 0.5 to 10 ng/ml.
Microinjections were performed at the Caliper Life Sciences facility and Rat Transgenic Nantes facilities. Outbred SD/Hsd (wild-type [wt]) strain animals were housed in standard microisolator cages under approved animal care protocols in an animal facility that is accredited by the Association for the Assessment and Accreditation for Laboratory Animal Care. The rats were maintained on a 14-10 h light/dark cycle with ad libitum access to food and water. Four to 5-wk-old SD/Hsd female rats were injected with 20-25 IU pregnant mare serum gonadotropin (Sigma-Aldrich) followed 48 h later with 20-25 IU human chorionic gonadotropin (Sigma-Aldrich) before breeding to outbred SD/Hsd males. Fertilized single-cell stage embryos were collected for subsequent microinjection. Manipulated embryos were transferred to pseudopregnant SD/Hsd female rats to be carried to parturition.
Multifeature human Ig rats (human IgH, Igk, and Igl in combination with rat J knockout (KO), kKO, and lKO) and wt, as control, were analyzed at 10-18 wk age. The animals were bred at Charles River under specific pathogen-free conditions.
All animal procedures involving the care and use of OmniRat were in accordance with the guidelines set forth in the Guide for the Care and Use of Laboratory Animals (available at: http://grants.nih.gov/grants/ olaw/Guide-for-the-Care-and-Use-of-Laboratory-Animals.pdf), which are adapted from the requirements of the Animal Welfare Act or regulations concerning the ethics of science research in the INSERM Unité Mixte de Recherche 1064 animal facility and approved by the regional ethics and veterinary commissions (no. F44011).
PCR and RT-PCR
Transgenic rats were identified by PCR from tail or ear clip DNA using an Isolate genomic DNA mini kit (Bioline). For IgH PCRs #1 kb GoTaq Green Master mix was used (Promega) following the general guidelines provided for this enzyme, with details given in Supplemental Table I . For IgH PCRs .1 kb KOD polymerase (Novagen) was used with standard cycling conditions but with an extension time of 90 s. The Igk and Igl PCR used Green Master mix as described above.
RNA was extracted from blood using the RiboPure blood kit (Ambion) and from spleen, bone marrow, or lymph nodes used the RNAspin mini kit (GE Healthcare). cDNA was made using oligo(dT) and Promega reverse transcriptase at 42˚C for 1 h. GAPDH PCR reactions (oligonucleotides 429-430) confirmed that RNA extraction and cDNA synthesis were successful. RT-PCRs were set up using V H leader primers with rat mC H 2 or rat gC H 2 primers (Supplemental Table I ), and GoTaq Green Master mix PCR products of the expected size were either purified by gel or QuickClean (Bioline) and sequenced directly or cloned into pGem-T (Promega).
Protein purification
IgM was purified on anti-IgM affinity matrix (CaptureSelect no. 2890.05; BAC, Naarden, The Netherlands,) as described in the protocol. Similarly, human Igk and Igl was purified on anti-L chain affinity matrix (CaptureSelect anti-Igk no. 0833 and anti-Igl no. 0849) according to the protocol.
For rat IgG purification (34) protein A and protein G-agarose was used (Innova Biosciences, Cambridge, U.K., nos. 851-0024 and 895-0024). Serum was incubated with the resin and binding was facilitated at 0.1 M sodium phosphate pH 7 for protein G and pH 8 for protein A under gentle mixing. Poly-Prep columns (Bio-Rad) were packed with the mixture and washed extensively with PBS (pH 7.4). Elution buffer was 0.1 M sodium citrate (pH 2.5) and neutralization buffer was 1 M Tris-HCl (pH 9).
Electrophoresis was performed on 4-15% SDS-PAGE and Coomassie brilliant blue was used for staining. Molecular mass standards were HyperPAGE prestained protein marker (BIO-33066; Bioline).
Flow cytometry analysis and fluorescence in situ hybridization
Cell suspensions were washed and adjusted to 5 3 10 5 cells/100 ml in PBS/ 1% BSA/0.1% sodium azide. Different B cell subsets were identified using mouse anti-rat IgM FITC-labeled mAb (MARM4; Jackson ImmunoResearch Laboratories) in combination with anti-B cell CD45R (rat B220) PE-conjugated mAb (His24; BD Biosciences). A FACSCanto II flow cytometer and FlowJo software (Becton Dickinson, Pont de Claix, France) were used for the analysis (35) .
Fluorescence in situ hybridization was carried out on fixed blood lymphocytes using purified IgH and IgL C region BAC (36).
Immunization, cell fusion, and affinity measurement
Immunizations were performed with 125 mg progranulin (PGRN) in CFA, 150 mg human growth hormone receptor (hGHR) in CFA, 200 mg TAU/ keyhole limpet hemocyanin (KLH) in CFA, 150 mg hen egg lysozyme (HEL) in CFA, and 150 mg OVA in CFA at the base of the tail and medial iliac lymph node cells were fused with mouse P3X63Ag8.653 myeloma cells 22 d later as described (37) . For multiple immunizations, protein, 125 mg PGRN or hen egg lysozyme, or 100 mg human growth hormone receptor or CD14 in GERBU adjuvant (http://www.Gerbu.com) were administered i.p. as follows: days 0, 14, 28, and day 41 without adjuvant, followed by spleen cell fusion with P3X63Ag8.653 cells 4 d later (3) .
Binding kinetics were analyzed by surface plasmon resonance using a Biacore 2000 with the Ags directly immobilized as described (19) .
Results
The human IgH and IgL loci
Construction of the human Ig loci employed established technologies to assemble large DNA segments using YACs and BACs (23, 29, (38) (39) (40) . As multiple sequential BAC modifications in E. coli frequently led to the deletion from the BAC of repetitive regions such as Ig switch sequences or of elements in the vicinity of the IgH 39 enhancers, a strategy was developed to assemble these large transloci by homologous recombination in S. cerevisiae as cYAC and, subsequently, converting such a cYAC into a BAC. The advantages of YACs include their large size, their sequence stability, and the ease of homologous alterations in the yeast host. BACs propagated in E. coli offer the advantages of easy preparation and large yield. Furthermore, detailed restriction mapping and sequencing analysis can be better achieved in BACs than in YACs.
The structures of the assembled chimeric IgH (human V H , D, and J H segments followed by rat C genes) and human Igk BACs as well as of the human Igl YAC are depicted in Fig. 1 . The integrated IgH and IgL transloci were then generated by coinjecting multiple BACs into fertilized rat oocytes, exploiting the previous finding that coinjection of overlapping DNA constructs often leads to cointegration into the genome (29) . Thus, the IgH translocus was created by coinsertion of BAC6-VH3-11 (a 182-kb AsiSI-AscI fragment containing 13 V H s) with BAC3 (a 173-kb NotI fragment containing 10 V H s) and BAC3-1N12M5I8 (human/rat Annabel, a 193-kb NotI fragment containing human V H 6-1 and all Ds and J H s followed by the rat C region). This resulted in the reconstitution of a fully functional IgH locus in the rat genome. Similarly, the human Igk locus was integrated by homologous overlaps (D9 containing Vk genes, a 150-kb NotI fragment; E24, containing Vks, Jks, and Ck on a 150-kb NotI fragment; and F17, a 40-kb PacI fragment containing Jks, Ck, and the KDE). The human Igl locus was isolated intact as an ∼300-kb YAC and also fully inserted into a rat chromosome. The integration success was identified in several founders each by transcript analysis that showed V(D)J-C recombinations from the most 59 to the most 39 end of the locus injected. Multiple BAC insertions were identified by quantitative PCR using V H -and C H -specific oligonucleotides (not shown) and it is likely that headto-tail integrations occurred. In all cases, transgenic animals with single-site integrations were generated by breeding.
Breeding to homozygosity
The derivation of the transgenic rats by DNA microinjection into oocytes, as well as their breeding and immunization, were carried out by a strategy similar to that previously used with the humanized mice (15, 16, 41) . However, a different approach was needed to achieve inactivation of the endogenous rat Ig loci because targeted gene inactivation in embryonic stem cells is not a technology that has been developed in the rat. We therefore used ZFN technology, an approach that has only been reported recently (42, 43) , to obtain rat lines with targeted inactivation of their IgH, Igk, and Igl loci (the inactivation of the rat IgH locus was described in Ref. 35 , and a manuscript describing inactivation of rat Igk and Igl is in preparation [by M.J. Osborn, S. Avis, R. Buelow, and M. Brüggemann]).
Analysis of the translocus integration by PCR as well as by fluorescence in situ hybridization (FISH) ( Table I ) revealed integration of all injected BACs in completion. Several founder rats carried low translocus copy numbers, with the rat C gene BAC in OmniRat likely to be fully integrated in five copies as determined by quantitative PCR of Cm and Ca products (not shown). Identification by FISH of single position insertion in many lines confirmed that multiple integration of BAC mixtures into different rat chromosomes was rare. Rats carrying the individual human transloci (IgH, Igk, and Igl) were crossbred successfully to homozygosity with Ig locus KO rats. This produced a highly efficient new multifeature line (OmniRat) with human V H -D-J H regions of .400 kb containing 22 functional V H s and a rat C region of ∼116 kb.
B cell development in the KO background
Flow cytometric analyses were performed to assess whether the introduced human Ig loci were capable of reconstituting normal B cell development. Particular differentiation stages were analyzed in spleen and bone marrow lymphocytes (Fig. 2) , which previously showed a lack of B cell development in JKO/JKO rats (35) , as well as no respective IgL expression in kKO/kKO and lKO/lKO animals (data not shown). Most striking was the complete recovery of B cell development in OmniRat compared with wt animals, with similar numbers of B220(CD45R) + lymphocytes in bone marrow and spleen. IgM expression in a large proportion of CD45R + B cells marked a fully reconstituted immune system. Separation of spleen cells was indistinguishable between OmniRat and wt animals and thus was successfully restored in the transgenic rats expressing human idiotypes with rat C region. Moreover, a small population of surface IgG + spleen lymphocytes was present in OmniRat (Fig.  2, right) .
Other lymphoid populations (as judged by flow cytometric staining for CD3, CD4, and CD8) were unaltered in OmniRat as compared with control animals (data not shown), which further supports the notion that optimal immune function has been completely restored. (44) were used (Table II) . Human V H genes were associated with diverse human D and J H segments linked to both rat Cm and Cg. Similarly, RT-PCR analysis of L chain transcripts showed extensive use and diversity. The analysis of class switch and hypermutation (Fig. 3) showed that both of these processes are operating effectively on the OmniRat IgH locus. Amplification of IgG switch products from PBLs revealed an extensive rate of mutation (.2 aa changes) in most cells (∼80%) and in near equal numbers of g1 and g2b H chains. A small percentage of trans-switch sequences, g2a and 2c, were also identified, which supports the observation that the translocus is similarly active, but providing human (V H -D-J H )s, as the endogenous IgH locus (45) . The number of mutated human Igl and Igk L chain sequences is ∼30% and thus appears to be less pronounced than what has been found for IgG H chains. The reason is that L chain RT-PCR products are amplified from both IgM, which is less mutated, and IgG-producing cells rather than from IgG + or differentiated plasma cells. Table I ). Mutated transswitch products were identified for human V H -rat Cg2a (4) and human V H -rat Cg2c (2).
Ig levels in serum
To gain unambiguous information about Ab production we compared quality and quantity of serum Ig from ∼3-mo-old OmniRat and normal wt animals housed in pathogen-free facilities. Purification of IgM and IgG separated on SDS-PAGE under reducing conditions (Fig. 4) showed the expected size, that is, ∼75 kDa for m, ∼55 kDa for g H chains, and ∼25 kDa for L chains, and was indistinguishable between OmniRat and wt animals. The yield of Ig from serum was found in both OmniRat and wt animals to be 100-300 mg/ml for IgM and 1-3 mg/ml for IgG. However, as rat IgG purification on protein A or G is seen as suboptimal (34), rat Ig levels may be underrepresented. The results from these naive animals compares well with the IgM levels of 0.5-1 mg/ml and IgG levels of several milligrams per milliliter reported for rats kept in open facilities (46, 47) . Interestingly, we were able to visualize class-specific mobility of rat IgG isotypes on SDS-PAGE (34) with a distinct lower size band for g2a H chains (Fig. 4B) . This band is missing in OmniRat owing to the lack of Cg2a in the translocus. However, because the IgG levels were similar between OmniRat and wt animals, we assume class switching is similarly efficient, albeit using different C genes. Purification of human Igk and Igl by capturing with anti-L chain was also successful (Fig.  4C, 4D ) with H and L chain bands of the expected size. Confirmation of the IgM/G titers was also obtained by ELISA, which determined wt and OmniRat isotype distribution and identified comparable amounts of IgG1 and IgG2b (not shown).
A direct comparison of human Ig L chain titers in solid phase titrations (Fig. 4E, 4F ) revealed 5-to 10-fold lower levels in OmniRat animals than in human serum. However, this was expected, as human control serum from mature adults can sometimes contain .10-fold higher Ig levels than in children up to their teens (48) , which would be similar to the human Igk and Igl titers in young rats. Although wt rats produce very little endogenous Igl, transgenic rats can efficiently express both types of human L chain, Igk and Igl.
Fully human Ag-specific IgG
Several cell fusions were carried out using either a rapid one immunization scheme and harvesting lymph nodes or, alternatively, using booster immunizations and spleen cells (Table III, Table IV) . For example, a considerable number of stable hybridomas were obtained after one immunization with human PGRN and myeloma fusion 22 d later. In this study, cell growth was observed in ∼3520 and ∼1600 wells in SD control and OmniRat hybridoma clones, respectively. Anti-PGRN-specific IgG, characterized by biosensor measurements, was produced by 148 OmniRat clones. Limiting dilution, to exclude mixed wells, and repeat affinity measurements revealed that OmniRat clones retain their Ag specificity. A comparison of association and dissociation rates of Abs from SD and OmniRat clones showed similar affinities between 0.3 and 74 nM (Tables III, IV , and data not shown). Single immunizations with hGHR, TAU receptor coupled to KLH (TAU/KLH), HEL, or OVA, followed by lymph node fusions, also produced many high-affinity human Abs often at similar numbers compared with wt.
Furthermore, conventional booster immunizations with human PGRN, hGHR, human CD14, and HEL resulted in high affinities (picomolar range) of IgG with human idiotypes. OmniRat animals always showed the expected 4-to 5-log titer increase of Ag-specific serum IgG, similar to and as pronounced as wt rats (Table III) . Although the results could vary from animal to animal, comparable numbers of hybridomas producing Ag-specific Abs with similarly high affinities were obtained from wt animals (SD and other strains) and the OmniRat strain. A summary of individual IgG-producing lymph node and spleen cell fusion clones, showing their diverse human V H -D-J H , human Vk-Jk, or Vl-Jl characteristics and affinities, are presented in Table IV . The immunization and fusion results showed that affinities well ,1 nM (determined by biosensor analysis) were frequently obtained from OmniRat animals immunized with PGRN, CD14, TAU, HEL, and OVA Ags. In summary, Ag-specific hybridomas from OmniRats could be as easily generated as from wt animals yielding numerous mAbs with subnanomolar affinity even after a single immunization.
Discussion
Assembling a novel IgH locus comprising human V H , D, and J H gene segments linked to a large part of the rat C H region has resulted in a highly efficient and near-normal expression level of Abs with human idiotypes. The combination of this chimeric IgH FIGURE 4. Purification of rat Ig with human idiotypes and comparison with human and normal rat Ig levels. OmniRat serum and human or rat wt control serum, 100 ml each, was used for IgM/G purification. (A) IgM was captured with anti-IgM matrix, which identified 14 mg in wt rat and 30 and 10 mg in OmniRat animals (HC14(a) and HC14(b)). (B) IgG was purified on protein A and protein G columns, with a yield of up to ∼3 mg/ml for OmniRat (protein A: HC14(a), 1000 mg/ml; HC14(b), 350 mg/ml; wt rat, 350 mg/ml; protein G: HC14(a), 2970 mg/ml; HC14(b), 280 mg/ml; wt rat, 1010 mg/ml). (C) Human Igk and (D) human Igl was purified on anti-Igk and anti-Igl matrix, respectively. No purification product was obtained using wt rat serum (not shown). Purified Ig, ∼3 mg (concentration determined by NanoDrop), was separated on 4-15% SDS-PAGE under reducing conditions. Comparison by ELISA titration of (E) human Igk and (F) human Igl levels in individual OmniRat animals (8531, 8322, 8199, 8486, 8055), human, and wt rat serum. Serum dilution (1:10, 1:100, 1:1,000, 1:10,000) was plotted against binding measured by adsorption at 492 nm. Matching name/numbers refer to samples from the same rat.
locus with human Igk and Igl loci has further revealed that chimeric Ab with fully human specificity is readily produced by the rats and that these chimeric IgH chains associate well with human IgL chains.
The excellent performance of these transgenic Ig loci with respect to the reconstitution of B cell development, the high titers of serum Ig, and the efficacy with which high-affinity Abs are obtained most probably derives from the fact that the C region of the IgH tranlocus is of endogenous (rat) origin. This could be reflected in several aspects of its performance. The quality of an immune response is known to rely on the combined actions of many signaling and modifier components associated with the B cell Ag receptor (see: http://www.biocarta.com/pathfiles/h_bcrpathway.asp). The use of rat IgH C regions should ensure efficient physiological interaction of the translocus-encoded membrane Ig with those endogenous components of the B cell Ag receptor (CD79A and CD79B) and other host Ag receptor-associated molecules that are necessary for efficient B cell activation. The use of rat IgH C regions will also allow physiological interaction with the various host Fc receptors implicated in immune response regulation (49, 50) .
However, a distinct attraction of using an IgH translocus in which the IgH C regions are of endogenous origin is that regions toward the 39 end of the IgH locus are known to play a major role in achieving efficient Ig class switch recombination as well, probably as optimal IgV gene somatic hypermutation (19, 51, 52) . There are substantial differences between mouse/rat and human in the sequences in this enhancer region of the IgH locus, located some 30 kb downstream of Ca (53) . The use of endogenous rat sequences for this region of the OmniRat IgH locus may well contribute to the efficient performance in Ab class switching and affinity maturation displayed by this rat strain.
The creation of OmniRat was assisted by several technical aspects. The strategy of combining YAC and BAC technologies allowed the suitability of yeast to be exploited for the faithful engineering of large loci containing multiple repeats, and the use of E. coli allowed the production of high DNA yields, which aided locus characterization as well as oocyte microinjection. This circumvented both the often problematic engineering of large transloci that harbor multiple repeat sequences in E. coli and obtaining high concentrations of translocus DNA, which is not readily accomplished from yeast.
The assembling of the transgenic IgH locus in the rat genome was also facilitated by the finding that different DNA constructs carrying distinct parts of the IgH locus can cointegrate at a single site of genomic integration, thereby allowing a large translocus to be recreated by cointegration of smaller sections. Overlapping integration has been reported previously, but for much smaller regions (,100 kb) (29, 54) . Our results in this study suggest that cointegration of simultaneously injected constructs, probably by homology but possibly in tandem, is quite a frequent event. This is very helpful because there is a limit to the size of individual DNA molecules that can be manipulated in vitro and microinjected into eggs without risk of shearing. The usual alternative strategy for generating animals containing very large transloci would be via Individual clones from the fusions in Table III. integration of YACs into stem cells and subsequent animal derivation (39, 55) ; this can prove quite laborious, especially in animals such as rats where there is limited experience with stem cell technology.
A further major aspect of the technical strategy that had facilitated the creation of OmniRat was the use of ZFN technology in fertilized rat oocytes to inactive the endogenous rat Ig loci (35, 42) . Because there is no established method for targeted gene recombination in rat embryonic stem cells, we had to devise a strategy distinct from that which has been previously used for target gene inactivation in the mouse. However, the ready success of this application of ZFN technology in rat eggs suggests that this may well be the future technology of choice for gene disruptions and replacement.
The diverse high expression of the transgenic Ig loci in OmniRat is further demonstrated in rats in which an endogenous Ig locus was intact and good titers of Ag-specific human Ig as well as hybridomas expressing high-affinity human mAbs could be obtained following immunization. Thus, in these rats containing a chimeric human/rat IgH locus together with human IgL translocus, the transloci compete very effectively in terms of performance with the endogenous rat Ig loci. A comparison of immunization results, based on Ag-binding and isotype (see Tables III, IV) , would make it near impossible to identify whether the results were obtained from normal wt rats or from OmniRat. This appears to be very different from the selected transgenic human Ab results made available and from the experience we had respective to the relative performance of the transloci and endogenous loci in mice carrying fully human IgH transloci (15, 19, 55) .
Following fusions of spleen and lymph node cells, OmniRat yielded a range of specific IgG Abs in response to immunization with a variety of Ags. These Abs displayed a diversity in epitope recognition comparable to that obtained using wt control rats. The molecular diversity of the Abs produced was considerable, with contributions as anticipated (44) from nearly all the V, D, and J gene sequences on the transloci segments. This was in stark contrast to some mice carrying fully human transloci where selective clonal expansion of relatively few precursor B cells was found to yield only limited molecular diversity (19, 55) . Thus, for example, five-feature mice expressing fully human Ab repertoires showed a substantial reduction in the frequency of IgM + B cells in the bone marrow from the pre-B-cell stage onward: frequencies were 21% of those observed in wt mice (56) . The five-feature mice also showed a substantial reduction of splenic IgM + B cells (∼35% of controls) (17) . Furthermore, although the extent of this reduction was variable, the frequency of splenic IgM + B cells in the humanized five-feature mice was always less than that in controls, whereas OmniRat consistently gave the same frequency of splenic IgM + cells as observed in wt animals. The fact that the number of transplanted V genes in OmniRat is only about half of those present in humans does not appear to have led to any significant restriction in the diversity of the immune response. Comparison of the CDR3 diversity in .1000 B cell clones (sequences can be provided) revealed the same extensive junctional differences in OmniRat animals as observed in wt control rats. When identical combinations of V, D, and J segments were very occasionally observed, differences between these sequences due to either N sequence addition/deletion or hypermutation were nevertheless observed. Extensive diversity was also seen for the introduced human Igk and Igl loci, similar to what has previously been observed with mice transgenic for human Ig loci (17, 19, 24) . Hence, the compromised efficiency in the production of human Abs observed with mice carrying fully human Ig transloci (13) has been overcome in OmniRat: these rats generate enormous diversity of V(D)J gene rearrangements from their transloci with efficient subsequent somatic hypermutation and class switching, leading to the production of high-affinity IgG Abs as a matter of routine. The yield of transgenic serum IgG and the level of IgV gene somatic hypermutation observed in the Agspecific mAbs obtained from the OmniRat strain revealed that clonal diversification and levels of serum Ab production were similar in OmniRat and control animals. Routine generation of high-affinity specificities in the subnanomolar range was accomplished by different single immunizations and compared favorably with wt animals.
In summary, this reveals that to maximize human Ab production, the best approach is to use an IgH locus with human V(D)J gene segments, so as to yield human Ag-specific binding sites, but rodent C genes and control sequences to ensure efficient B cell differentiation, high Ab expression, and diversification. For therapeutic applications, the rat C H regions in mAbs obtained from OmniRat can readily be replaced by human C H regions without compromising Ag-specificity during the bulking up phase of mAb production.
